What is the recommended medication management pathway for hyperlipidemia?

Medication Management Pathway for Hyperlipidemia

The medication management pathway for hyperlipidemia is fundamentally risk-stratified, with high-intensity statin therapy as the cornerstone for patients with established ASCVD (targeting ≥50% LDL-C reduction), followed by sequential addition of ezetimibe, then PCSK9 inhibitors or bempedoic acid for those not achieving LDL-C <70 mg/dL on maximally tolerated statin therapy. 1

Initial Risk Assessment and Baseline Testing

• Measure fasting or nonfasting lipid profile in all adults ≥20 years to establish baseline LDL-C and estimate ASCVD risk 1
• If nonfasting triglycerides ≥400 mg/dL, repeat fasting lipid profile for accurate LDL-C assessment 1
• For patients with family history of premature ASCVD or suspected genetic hyperlipidemia, obtain fasting lipid profile to identify familial disorders 1
• Consider referral to lipid specialist for patients with baseline LDL-C ≥190 mg/dL or those with ASCVD not achieving targets on combination therapy 1

Primary Prevention Pathway (No ASCVD)

Baseline LDL-C ≥190 mg/dL

• Initiate high-intensity statin therapy immediately (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) 1
• Target ≥50% LDL-C reduction 1
• If target not achieved on maximally tolerated statin, add ezetimibe 10 mg daily (provides additional 18-25% LDL-C reduction) 1
• If still not at goal, consider PCSK9 inhibitor (alirocumab 75-150 mg SC every 2 weeks or evolocumab 140 mg SC every 2 weeks) 1

Moderate-to-High Risk (10-year ASCVD risk ≥7.5%)

• Initiate moderate-to-high intensity statin therapy based on risk level 1
• Consider coronary artery calcium (CAC) scoring to refine risk assessment and inform treatment intensity 2
• Escalate therapy if LDL-C goals not met using sequential approach outlined above 3

Secondary Prevention Pathway (Established ASCVD)

Standard ASCVD Patients (Age ≤75 years)

• Initiate or continue high-intensity statin therapy immediately targeting ≥50% LDL-C reduction 1
• LDL-C goal: <70 mg/dL (non-HDL-C <100 mg/dL) 1, 3
• If high-intensity statin contraindicated or not tolerated, use moderate-intensity statin (targeting 30-49% reduction) 1

Very High-Risk ASCVD Patients

Very high-risk includes: recent acute coronary syndrome, recurrent events, multivessel disease, or baseline LDL-C ≥190 mg/dL 1

Sequential Treatment Algorithm:

1. Start with maximally tolerated statin (high-intensity preferred) 1

2. Add ezetimibe 10 mg daily if not at LDL-C goal

   • Provides additional 18-25% LDL-C reduction 1
   • Well-tolerated, generic available, proven CV outcomes benefit in IMPROVE-IT trial 1
   • Take 2 hours before or 4 hours after bile acid sequestrants if used in combination 1

3. Add PCSK9 inhibitor if LDL-C remains ≥70 mg/dL on statin plus ezetimibe 1

   • Alirocumab: Start 75 mg SC every 2 weeks, increase to 150 mg if needed (45-58% additional LDL-C reduction) 1
   • Evolocumab: 140 mg SC every 2 weeks or 420 mg monthly (58-64% additional LDL-C reduction) 1
   • Both proven to reduce CV death, MI, and stroke in outcomes trials (ODYSSEY Outcomes, FOURIER) 1
   • Prioritize PCSK9i in patients with elevated Lp(a) who may derive greater benefit 2

4. Alternative to PCSK9i: Bempedoic acid 180 mg daily

   • Provides 17-18% additional LDL-C reduction when added to statin 1
   • Useful option for cost-sensitive situations or when PCSK9i not accessible 3
   • Does not require injection 4

Post-Acute Coronary Syndrome

• Immediately initiate high-intensity statin, preferably combined with ezetimibe at time of ACS 5
• This aggressive early approach is now emphasized in 2025 ESC guidelines 5
• Do not delay combination therapy in this highest-risk population 5

Special Considerations for Statin Intolerance

• If patient experiences statin-associated muscle symptoms with ≥2 different statins (including trial at lowest FDA-approved dose and alternative dosing regimens like every-other-day), refer to lipid specialist 1
• Consider ezetimibe monotherapy (18% LDL-C reduction) as foundation 1
• Add bempedoic acid (does not cause myopathy as it's not activated in muscle tissue) 1, 4
• Consider PCSK9 inhibitor as monotherapy or in combination 1

Hypertriglyceridemia Management

• For patients with ASCVD or increased ASCVD risk and elevated triglycerides on statin therapy, add icosapent ethyl (EPA) 2 grams twice daily 3
• Do not use combination EPA plus DHA products for ASCVD risk reduction 3
• Strongly avoid niacin - no CV benefit and significant adverse effects 3
• Fibrates not recommended as add-on to statins for CV outcomes 1, 6

Monitoring and Follow-up

• Recheck lipid panel 4-12 weeks after initiating or adjusting therapy 1
• Monitor hepatic transaminases when using ezetimibe with statin per statin monitoring recommendations 1
• Assess for statin-associated muscle symptoms at each visit 1
• For patients on PCSK9 inhibitors, monitor for injection site reactions and hypersensitivity 1

Critical Pitfalls to Avoid

• Do not delay statin intensification or combination therapy in very high-risk patients hoping lifestyle changes alone will suffice 1
• Do not use fibrates or niacin as add-on therapy to statins for ASCVD prevention - no proven benefit 1, 3
• Do not stop statins due to mild transaminase elevations (<3x upper limit normal) without considering other causes 1
• Do not use LDL-C <30 mg/dL as reason to avoid therapy - very low LDL-C levels are safe and provide additional benefit in very high-risk patients 2
• Do not forget to refer complex cases (baseline LDL-C ≥190 mg/dL with ASCVD, multiple statin intolerance, failure to achieve goals on triple therapy) to lipid specialists 1

Referral Considerations

• Refer to registered dietitian/nutritionist for all patients with ASCVD or LDL-C ≥190 mg/dL to optimize dietary management 1
• Refer to lipid specialist for patients not achieving LDL-C <70 mg/dL and ≥50% reduction on maximally tolerated statin plus nonstatin therapy 1
• Virtual lipid specialist consultations may be available for rural/remote patients 1